Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight.

Bandres-Ciga S, Ahmed S, Sabir MS, Blauwendraat C, Adarmes-Gómez AD, Bernal-Bernal I, Bonilla-Toribio M, Buiza-Rueda D, Carrillo F, Carrión-Claro M, Gómez-Garre P, Jesús S, Labrador-Espinosa MA, Macias D, Méndez-Del-Barrio C, Periñán-Tocino T, Tejera-Parrado C, Vargas-González L, Diez-Fairen M, Alvarez I, Tartari JP, Buongiorno M, Aguilar M, Gorostidi A, Bergareche JA, Mondragon E, Vinagre-Aragon A, Croitoru I, Ruiz-Martínez J, Dols-Icardo O, Kulisevsky J, Marín-Lahoz J, Pagonabarraga J, Pascual-Sedano B, Ezquerra M, Cámara A, Compta Y, Fernández M, Fernández-Santiago R, Muñoz E, Tolosa E, Valldeoriola F, Gonzalez-Aramburu I, Sanchez Rodriguez A, Sierra M, Menéndez-González M, Blazquez M, Garcia C, Suarez-San Martin E, García-Ruiz P, Martínez-Castrillo JC, Vela-Desojo L, Ruz C, Barrero FJ, Escamilla-Sevilla F, Mínguez-Castellanos A, Cerdan D, Tabernero C, Gomez Heredia MJ, Perez Errazquin F, Romero-Acebal M, Feliz C, Lopez-Sendon JL, Mata M, Martínez Torres I, Kim JJ, Dalgard CL; American Genome Center, Brooks J, Saez-Atienzar S, Gibbs JR, Jorda R, Botia JA, Bonet-Ponce L, Morrison KE, Clarke C, Tan M, Morris H, Edsall C, Hernandez D, Simon-Sanchez J, Nalls MA, Scholz SW, Jimenez-Escrig A, Duarte J, Vives F, Duran R, Hoenicka J, Alvarez V, Infante J, Marti MJ, Clarimón J, López de Munain A, Pastor P, Mir P, Singleton A; International Parkinson Disease Genomics Consortium.

Mov Disord. 2019 Oct 29. doi: 10.1002/mds.27864. [Epub ahead of print]

PMID:
31660654
2.

Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease.

Podlesniy P, Puigròs M, Serra N, Fernández-Santiago R, Ezquerra M, Tolosa E, Trullas R.

EBioMedicine. 2019 Oct;48:554-567. doi: 10.1016/j.ebiom.2019.09.015. Epub 2019 Oct 17.

3.

HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease.

Gaig C, Ercilla G, Daura X, Ezquerra M, Fernández-Santiago R, Palou E, Sabater L, Höftberger R, Heidbreder A, Högl B, Iranzo A, Santamaria J, Dalmau J, Graus F.

Neurol Neuroimmunol Neuroinflamm. 2019 Aug 12;6(6). pii: e605. doi: 10.1212/NXI.0000000000000605. Print 2019 Nov.

4.

Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients.

Fernández-Santiago R, Merkel A, Castellano G, Heath S, Raya Á, Tolosa E, Martí MJ, Consiglio A, Ezquerra M.

Clin Epigenetics. 2019 Jul 23;11(1):108. doi: 10.1186/s13148-019-0701-6.

5.

SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.

Fernández-Santiago R, Martín-Flores N, Antonelli F, Cerquera C, Moreno V, Bandres-Ciga S, Manduchi E, Tolosa E, Singleton AB, Moore JH; International Parkinson's Disease Genomics Consortium, Martí MJ, Ezquerra M, Malagelada C.

Mov Disord. 2019 Sep;34(9):1333-1344. doi: 10.1002/mds.27770. Epub 2019 Jun 24.

PMID:
31234232
6.

CCAAT/enhancer binding protein δ is a transcriptional repressor of α-synuclein.

Valente T, Dentesano G, Ezquerra M, Fernandez-Santiago R, Martinez-Martin J, Gallastegui E, Domuro C, Compta Y, Martí MJ, Bachs O, Márquez-Kisinousky L, Straccia M, Solà C, Saura J.

Cell Death Differ. 2019 Jun 17. doi: 10.1038/s41418-019-0368-8. [Epub ahead of print]

PMID:
31209363
7.

Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations.

González-Casacuberta I, Juárez-Flores DL, Ezquerra M, Fucho R, Catalán-García M, Guitart-Mampel M, Tobías E, García-Ruiz C, Fernández-Checa JC, Tolosa E, Martí MJ, Grau JM, Fernández-Santiago R, Cardellach F, Morén C, Garrabou G.

Aging (Albany NY). 2019 Jun 9;11(11):3750-3767. doi: 10.18632/aging.102014.

8.

Parkinson's disease as a systemic pathology.

Ezquerra M, Martí MJ, Fernández-Santiago R.

Aging (Albany NY). 2019 Feb 11;11(4):1081-1082. doi: 10.18632/aging.101824. No abstract available.

9.

MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.

Martín-Flores N, Fernández-Santiago R, Antonelli F, Cerquera C, Moreno V, Martí MJ, Ezquerra M, Malagelada C.

Mol Neurobiol. 2019 Mar;56(3):2092-2100. doi: 10.1007/s12035-018-1219-1. Epub 2018 Jul 10.

PMID:
29992529
10.

MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients.

Tolosa E, Botta-Orfila T, Morató X, Calatayud C, Ferrer-Lorente R, Martí MJ, Fernández M, Gaig C, Raya Á, Consiglio A, Ezquerra M, Fernández-Santiago R.

Neurobiol Aging. 2018 Sep;69:283-291. doi: 10.1016/j.neurobiolaging.2018.05.032. Epub 2018 May 31.

PMID:
29935433
11.

Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2 G2019S -Parkinson's disease.

Juárez-Flores DL, González-Casacuberta I, Ezquerra M, Bañó M, Carmona-Pontaque F, Catalán-García M, Guitart-Mampel M, Rivero JJ, Tobias E, Milisenda JC, Tolosa E, Marti MJ, Fernández-Santiago R, Cardellach F, Morén C, Garrabou G.

J Transl Med. 2018 Jun 8;16(1):160. doi: 10.1186/s12967-018-1526-3.

12.

Correction to: The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity.

Kim H, Calatayud C, Guha S, Fernández-Carasa I, Berkowitz L, Carballo-Carbajal I, Ezquerra M, Fernández-Santiago R, Kapahi P, Raya Á, Miranda-Vizuete A, Lizcano JM, Vila M, Caldwell KA, Caldwell GA, Consiglio A, Dalfo E.

Mol Neurobiol. 2018 Sep;55(9):7553-7554. doi: 10.1007/s12035-018-1010-3.

13.

Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations.

González-Casacuberta I, Morén C, Juárez-Flores DL, Esteve-Codina A, Sierra C, Catalán-García M, Guitart-Mampel M, Tobías E, Milisenda JC, Pont-Sunyer C, Martí MJ, Cardellach F, Tolosa E, Artuch R, Ezquerra M, Fernández-Santiago R, Garrabou G.

Neurobiol Aging. 2018 May;65:206-216. doi: 10.1016/j.neurobiolaging.2018.01.021. Epub 2018 Feb 7. Erratum in: Neurobiol Aging. 2018 Sep;69:300.

PMID:
29501959
14.

α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.

Fernández-Santiago R, Garrido A, Infante J, González-Aramburu I, Sierra M, Fernández M, Valldeoriola F, Muñoz E, Compta Y, Martí MJ, Ríos J, Tolosa E, Ezquerra M; Barcelona LRRK2 Study Group†.

Mov Disord. 2018 Apr;33(4):637-641. doi: 10.1002/mds.27295. Epub 2018 Feb 23.

PMID:
29473656
15.

The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity.

Kim H, Calatayud C, Guha S, Fernández-Carasa I, Berkowitz L, Carballo-Carbajal I, Ezquerra M, Fernández-Santiago R, Kapahi P, Raya Á, Miranda-Vizuete A, Lizcano JM, Vila M, Caldwell KA, Caldwell GA, Consiglio A, Dalfo E.

Mol Neurobiol. 2018 Sep;55(9):7533-7552. doi: 10.1007/s12035-018-0881-7. Epub 2018 Feb 10. Erratum in: Mol Neurobiol. 2018 Apr 2;:.

16.

Target-enriched sequencing of chromosome 17q21.31 in sporadic tauopathies reveals no candidate variants.

Razquin C, Ortega-Cubero S, Rojo-Bustamante E, Diez-Fairen M, Lorenzo E, Alonso E, Ezquerra M, Ross OA, Carcel M, Lorenzo-Betancor O, Soto AI, Burgess JD, Ertekin-Taner N, Dickson DW, Pastor MA, Tolosa E, Pastor P.

Neurobiol Aging. 2018 Jun;66:177.e7-177.e10. doi: 10.1016/j.neurobiolaging.2017.12.026. Epub 2018 Jan 11.

17.

Discovering the 3' UTR-mediated regulation of alpha-synuclein.

Marchese D, Botta-Orfila T, Cirillo D, Rodriguez JA, Livi CM, Fernández-Santiago R, Ezquerra M, Martí MJ, Bechara E, Tartaglia GG; Catalan MSA Registry (CMSAR).

Nucleic Acids Res. 2017 Dec 15;45(22):12888-12903. doi: 10.1093/nar/gkx1048.

18.

MAPT association with REM sleep behavior disorder.

Fernández-Santiago R, Iranzo A, Gaig C, Serradell M, Fernández M, Pastor P, Tolosa E, Santamaría J, Ezquerra M.

Neurol Genet. 2017 Jan 13;3(1):e131. doi: 10.1212/NXG.0000000000000131. eCollection 2017 Feb. No abstract available.

19.

Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population.

Giri A, Mok KY, Jansen I, Sharma M, Tesson C, Mangone G, Lesage S, Bras JM, Shulman JM, Sheerin UM; International Parkinson's Disease Consortium (IPDGC), Díez-Fairen M, Pastor P, Martí MJ, Ezquerra M, Tolosa E, Correia-Guedes L, Ferreira J, Amin N, van Duijn CM, van Rooij J, Uitterlinden AG, Kraaij R, Nalls M, Simón-Sánchez J.

Neurobiol Aging. 2017 Feb;50:167.e11-167.e13. doi: 10.1016/j.neurobiolaging.2016.10.004. Epub 2016 Oct 11.

20.

CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study.

Dangla-Valls A, Molinuevo JL, Altirriba J, Sánchez-Valle R, Alcolea D, Fortea J, Rami L, Balasa M, Muñoz-García C, Ezquerra M, Fernández-Santiago R, Lleó A, Lladó A, Antonell A.

Mol Neurobiol. 2017 Nov;54(9):6647-6654. doi: 10.1007/s12035-016-0106-x. Epub 2016 Oct 13.

PMID:
27738874
21.

Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations.

Cosín-Tomás M, Antonell A, Lladó A, Alcolea D, Fortea J, Ezquerra M, Lleó A, Martí MJ, Pallàs M, Sanchez-Valle R, Molinuevo JL, Sanfeliu C, Kaliman P.

Mol Neurobiol. 2017 Sep;54(7):5550-5562. doi: 10.1007/s12035-016-0088-8. Epub 2016 Sep 8.

PMID:
27631879
22.

Reply.

Tell-Martí G, Puig-Butille JA, Potrony M, Badenas C, Milà M, Malvehy J, Martí MJ, Ezquerra M, Fernández-Santiago R, Puig S.

Ann Neurol. 2016 May;79(5):868. doi: 10.1002/ana.24629. Epub 2016 Mar 22. No abstract available.

PMID:
26934067
23.

Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder.

Fernández-Santiago R, Iranzo A, Gaig C, Serradell M, Fernández M, Tolosa E, Santamaría J, Ezquerra M.

Neurology. 2016 Mar 15;86(11):1072-3. doi: 10.1212/WNL.0000000000002304. Epub 2016 Jan 8. No abstract available.

PMID:
26747879
24.

Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models.

Fernández-Santiago R, Ezquerra M.

Stem Cells Int. 2016;2016:9464591. doi: 10.1155/2016/9464591. Epub 2015 Nov 30. Review.

25.

Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients.

Fernández-Santiago R, Carballo-Carbajal I, Castellano G, Torrent R, Richaud Y, Sánchez-Danés A, Vilarrasa-Blasi R, Sánchez-Pla A, Mosquera JL, Soriano J, López-Barneo J, Canals JM, Alberch J, Raya Á, Vila M, Consiglio A, Martín-Subero JI, Ezquerra M, Tolosa E.

EMBO Mol Med. 2015 Dec;7(12):1529-46. doi: 10.15252/emmm.201505439.

26.

Reply.

Tell-Martí G, Puig-Butille JA, Potrony M, Badenas C, Milà M, Malvehy J, Martí MJ, Ezquerra M, Fernández-Santiago R, Puig S.

Ann Neurol. 2016 Jan;79(1):161-3. doi: 10.1002/ana.24526. Epub 2015 Dec 12. No abstract available.

PMID:
26389780
27.

3p14 De Novo Interstitial Microdeletion in a Patient with Intellectual Disability and Autistic Features with Language Impairment: A Comparison with Similar Cases.

de la Hoz AB, Maortua H, García-Rives A, Martínez-González MJ, Ezquerra M, Tejada MI.

Case Rep Genet. 2015;2015:876348. doi: 10.1155/2015/876348. Epub 2015 May 14.

28.

Reply: To PMID 25631192.

Tell-Martí G, Puig-Butille JA, Potrony M, Badenas C, Milà M, Malvehy J, Martí MJ, Ezquerra M, Fernández-Santiago R, Puig S.

Ann Neurol. 2015 Jul;78(1):153-4. doi: 10.1002/ana.24418. Epub 2015 May 25. No abstract available.

PMID:
25913870
29.

MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder.

Fernández-Santiago R, Iranzo A, Gaig C, Serradell M, Fernández M, Tolosa E, Santamaría J, Ezquerra M.

Ann Neurol. 2015 May;77(5):895-901. doi: 10.1002/ana.24384. Epub 2015 Mar 13.

PMID:
25675938
30.

The MC1R melanoma risk variant p.R160W is associated with Parkinson disease.

Tell-Marti G, Puig-Butille JA, Potrony M, Badenas C, Milà M, Malvehy J, Martí MJ, Ezquerra M, Fernández-Santiago R, Puig S.

Ann Neurol. 2015 May;77(5):889-94. doi: 10.1002/ana.24373. Epub 2015 Mar 13.

PMID:
25631192
31.

TREM2 R47H variant and risk of essential tremor: a cross-sectional international multicenter study.

Ortega-Cubero S, Lorenzo-Betancor O, Lorenzo E, Agúndez JA, Jiménez-Jiménez FJ, Ross OA, Wurster I, Mielke C, Lin JJ, Coria F, Clarimon J, Ezquerra M, Brighina L, Annesi G, Alonso-Navarro H, García-Martin E, Gironell A, Marti MJ, Yueh KC, Wszolek ZK, Sharma M, Berg D, Krüger R, Pastor MA, Pastor P.

Parkinsonism Relat Disord. 2015 Mar;21(3):306-9. doi: 10.1016/j.parkreldis.2014.12.010. Epub 2014 Dec 24.

32.

Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.

Gaig C, Vilas D, Infante J, Sierra M, García-Gorostiaga I, Buongiorno M, Ezquerra M, Martí MJ, Valldeoriola F, Aguilar M, Calopa M, Hernandez-Vara J, Tolosa E.

PLoS One. 2014 Oct 17;9(10):e108982. doi: 10.1371/journal.pone.0108982. eCollection 2014.

33.

An exome study of Parkinson's disease in Sardinia, a Mediterranean genetic isolate.

Quadri M, Yang X, Cossu G, Olgiati S, Saddi VM, Breedveld GJ, Ouyang L, Hu J, Xu N, Graafland J, Ricchi V, Murgia D, Guedes LC, Mariani C, Marti MJ, Tarantino P, Asselta R, Valldeoriola F, Gagliardi M, Pezzoli G, Ezquerra M, Quattrone A, Ferreira J, Annesi G, Goldwurm S, Tolosa E, Oostra BA, Melis M, Wang J, Bonifati V.

Neurogenetics. 2015 Jan;16(1):55-64. doi: 10.1007/s10048-014-0425-x. Epub 2014 Oct 8.

PMID:
25294124
34.

Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease.

Romaní-Aumedes J, Canal M, Martín-Flores N, Sun X, Pérez-Fernández V, Wewering S, Fernández-Santiago R, Ezquerra M, Pont-Sunyer C, Lafuente A, Alberch J, Luebbert H, Tolosa E, Levy OA, Greene LA, Malagelada C.

Cell Death Dis. 2014 Aug 7;5:e1364. doi: 10.1038/cddis.2014.333.

35.

Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease.

Botta-Orfila T, Morató X, Compta Y, Lozano JJ, Falgàs N, Valldeoriola F, Pont-Sunyer C, Vilas D, Mengual L, Fernández M, Molinuevo JL, Antonell A, Martí MJ, Fernández-Santiago R, Ezquerra M.

J Neurosci Res. 2014 Aug;92(8):1071-7. doi: 10.1002/jnr.23377. Epub 2014 Mar 20.

PMID:
24648008
36.

Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans.

Ortega-Cubero S, Lorenzo-Betancor O, Lorenzo E, Alonso E, Coria F, Pastor MA, Fernández-Santiago R, Martí MJ, Ezquerra M, Valldeoriola F, Compta Y, Tolosa E, Agundez JA, Jiménez-Jiménez FJ, Gironell A, Clarimon J, de Castro P, García-Martín E, Alonso-Navarro H, Pastor P.

Neurobiol Aging. 2013 Oct;34(10):2441.e9-2441.e11. doi: 10.1016/j.neurobiolaging.2013.04.024. Epub 2013 May 31.

PMID:
23731953
37.

Phenotypic variability within the inclusion body spectrum of basophilic inclusion body disease and neuronal intermediate filament inclusion disease in frontotemporal lobar degenerations with FUS-positive inclusions.

Gelpi E, Lladó A, Clarimón J, Rey MJ, Rivera RM, Ezquerra M, Antonell A, Navarro-Otano J, Ribalta T, Piñol-Ripoll G, Pérez A, Valldeoriola F, Ferrer I.

J Neuropathol Exp Neurol. 2012 Sep;71(9):795-805. doi: 10.1097/NEN.0b013e318266efb1.

PMID:
22892522
38.

Age at onset in LRRK2-associated PD is modified by SNCA variants.

Botta-Orfila T, Ezquerra M, Pastor P, Fernández-Santiago R, Pont-Sunyer C, Compta Y, Lorenzo-Betancor O, Samaranch L, Martí MJ, Valldeoriola F, Calopa M, Fernández M, Aguilar M, de Fabregas O, Hernández-Vara J, Tolosa E.

J Mol Neurosci. 2012 Sep;48(1):245-7. doi: 10.1007/s12031-012-9820-7. Epub 2012 Jun 6.

PMID:
22669510
39.

Brain transcriptomic profiling in idiopathic and LRRK2-associated Parkinson's disease.

Botta-Orfila T, Sànchez-Pla A, Fernández M, Carmona F, Ezquerra M, Tolosa E.

Brain Res. 2012 Jul 23;1466:152-7. doi: 10.1016/j.brainres.2012.05.036. Epub 2012 May 24.

PMID:
22634372
40.

Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.

Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I, Jiménez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patel B, Giralt A, Canals JM, Memo M, Alberch J, López-Barneo J, Vila M, Cuervo AM, Tolosa E, Consiglio A, Raya A.

EMBO Mol Med. 2012 May;4(5):380-95. doi: 10.1002/emmm.201200215. Epub 2012 Mar 8.

41.

LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation.

Lorenzo-Betancor O, Samaranch L, Ezquerra M, Tolosa E, Lorenzo E, Irigoyen J, Gaig C, Pastor MA, Soto-Ortolaza AI, Ross OA, Rodríguez-Oroz MC, Valldeoriola F, Martí MJ, Luquin MR, Perez-Tur J, Burguera JA, Obeso JA, Pastor P.

Mov Disord. 2012 Jan;27(1):146-51. doi: 10.1002/mds.23968. Epub 2011 Oct 28.

PMID:
22038903
42.

Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease.

Botta-Orfila T, Tolosa E, Gelpi E, Sànchez-Pla A, Martí MJ, Valldeoriola F, Fernández M, Carmona F, Ezquerra M.

Neurobiol Dis. 2012 Jan;45(1):462-8. doi: 10.1016/j.nbd.2011.08.033. Epub 2011 Sep 16.

PMID:
21946334
43.

Rapidly progressive diffuse Lewy body disease.

Gaig C, Valldeoriola F, Gelpi E, Ezquerra M, Llufriu S, Buongiorno M, Rey MJ, Martí MJ, Graus F, Tolosa E.

Mov Disord. 2011 Jun;26(7):1316-23. doi: 10.1002/mds.23506. Epub 2011 Apr 11.

PMID:
21484863
44.

123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations.

Valldeoriola F, Gaig C, Muxí A, Navales I, Paredes P, Lomeña F, De la Cerda A, Buongiorno M, Ezquerra M, Santacruz P, Martí MJ, Tolosa E.

J Neurol. 2011 Jun;258(6):1126-32. doi: 10.1007/s00415-010-5896-6. Epub 2011 Jan 8.

45.

Identifying the genetic components underlying the pathophysiology of movement disorders.

Ezquerra M, Compta Y, Marti MJ.

Appl Clin Genet. 2011 Jun 23;4:81-92. doi: 10.2147/TACG.S7333. Print 2011.

46.

Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease.

Botta-Orfila T, Ezquerra M, Ríos J, Fernández-Santiago R, Cervantes S, Samaranch L, Pastor P, Martí MJ, Muñoz E, Valldeoriola F, Aguilar M, Calopa M, Hernández-Vara J, Tolosa E.

Eur J Neurol. 2011 Mar;18(3):e32. doi: 10.1111/j.1468-1331.2010.03245.x. Epub 2010 Nov 4. No abstract available.

PMID:
21054681
47.

High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease.

Compta Y, Ezquerra M, Muñoz E, Tolosa E, Valldeoriola F, Rios J, Cámara A, Fernández M, Buongiorno MT, Marti MJ.

Neurosci Lett. 2011 Jan 7;487(2):169-73. doi: 10.1016/j.neulet.2010.10.015. Epub 2010 Oct 15.

PMID:
20951764
48.

Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy.

Ezquerra M, Pastor P, Gaig C, Vidal-Taboada JM, Cruchaga C, Muñoz E, Martí MJ, Valldeoriola F, Aguilar M, Calopa M, Hernandez-Vara J, Tolosa E.

Neurobiol Aging. 2011 Mar;32(3):547.e11-6. doi: 10.1016/j.neurobiolaging.2009.09.011. Epub 2009 Oct 29.

PMID:
19879020
49.

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.

Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Muñoz E, Ezquerra M, Ríos J, Tolosa E.

Mov Disord. 2009 Nov 15;24(15):2203-10. doi: 10.1002/mds.22594.

PMID:
19795497
50.

Parkinsonism, dysautonomia, REM behaviour disorder and visual hallucinations mimicking synucleinopathy in a patient with progressive supranuclear palsy.

Compta Y, Martí MJ, Rey MJ, Ezquerra M.

J Neurol Neurosurg Psychiatry. 2009 May;80(5):578-9. doi: 10.1136/jnnp.2007.142810. No abstract available.

PMID:
19372296

Supplemental Content

Loading ...
Support Center